{"id":964766,"date":"2026-05-19T10:31:28","date_gmt":"2026-05-19T14:31:28","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-gains-growing-institutional-support-ahead-of-key-brain-cancer-clinical-milestones\/"},"modified":"2026-05-19T10:31:28","modified_gmt":"2026-05-19T14:31:28","slug":"neonc-technologies-gains-growing-institutional-support-ahead-of-key-brain-cancer-clinical-milestones","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-gains-growing-institutional-support-ahead-of-key-brain-cancer-clinical-milestones\/","title":{"rendered":"NeOnc Technologies Gains Growing Institutional Support Ahead of Key Brain Cancer Clinical Milestones"},"content":{"rendered":"

\nAlliance Global Partners and Maxim Group Initiate Separate NeOnc Technologies Coverage with Favorable Ratings
\n<\/h2>\n
\n

DENVER, May 19, 2026 (GLOBE NEWSWIRE) — (www.247marketnews.com<\/u><\/a>) \u2013 NeOnc Technologies (NASDAQ:NTHI<\/a>), a clinical-stage biotechnology company focused on treatments for central nervous system (CNS) cancers, has recently attracted growing attention from Wall Street analysts, institutional investors, and company insiders as it advances its pipeline of novel brain cancer therapies.<\/p>\n

\n Maxim Group<\/a> and Alliance Global Partners initiated coverage on NeOnc with a favorable ratings and targets, highlighting what the firms see as significant benefit potential relative to the company\u2019s current market position. BTIG Research<\/a> also recently launched coverage with a advantageous rating and target, reflecting increasing analyst interest in NeOnc\u2019s differentiated CNS-focused platform.<\/p>\n

Investor confidence has been reinforced by substantial insider buying activity. Amir Heshmatpour, the company\u2019s CEO, Chairman, and President, has consistently purchased shares on the open market, with recent acquisitions totaling more than $500,000 and cumulative insider purchases approaching $1 million over the past year. The timing of these purchases, occurring ahead of anticipated clinical milestones, may signal management\u2019s confidence in the company\u2019s upcoming data readouts and broader platform potential.<\/p>\n

Institutional ownership has also continued to expand. Recent filings show multiple firms increasing their positions in the company, including Bank of America, State Street Corp, Barclays PLC, Westmount Partners, and Foundations Investment Advisors. While the dollar amounts vary, the continued accumulation by both institutional investors and insiders is viewed by some market participants as notable given the company\u2019s stage of development and upcoming catalysts.<\/p>\n

NeOnc is currently developing proprietary intranasal drug delivery technologies designed to bypass the blood-brain barrier, one of the most significant challenges in neuro-oncology. Its lead candidate, NEO100, is being evaluated in a fully enrolled Phase 2a clinical trial targeting aggressive brain tumors such as glioblastoma, with interim data expected in the near term. The company is also advancing NEO212, a hybrid therapeutic candidate that may have applications across multiple CNS malignancies and neurological conditions.<\/p>\n

The convergence of analyst coverage, insider accumulation, institutional participation, and approaching clinical milestones has increased visibility around the company as it continues development of its CNS oncology platform.<\/p>\n

Download the 24\/7 Market News App here https:\/\/app.247mnn.com\/<\/u><\/a> or on the App Store.<\/p>\n

\n Sources and Links;<\/strong>\n <\/p>\n